Imaging Epidermal Growth Factor Receptor Expression in Vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe
Overview
Authors
Affiliations
Purpose: To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)-overexpressing tumors from surrounding normal tissues that also expresses EGFR.
Experimental Design: Near-infrared (NIR) quantum dots (QD) were coupled to EGF using thiol-maleimide conjugation to create EGF-QD nanoprobes. In vitro binding affinity of these nanoprobes and unconjugated QDs was evaluated in a panel of cell lines, with and without anti-EGFR antibody pretreatment. Serial optical imaging of HCT116 xenograft tumors was done after systemic injection of QD and EGF-QD.
Results: EGF-QD showed EGFR-specific binding in vitro. In vivo imaging showed three distinct phases, tumor influx ( approximately 3 min), clearance ( approximately 60 min), and accumulation (1-6 h), of EGF-QD nanoprobes. Both QD and EGF-QD showed comparable nonspecific rapid tumor influx and clearance followed by attainment of an apparent dynamic equilibrium at approximately 60 min. Subsequently (1-6 h), whereas QD concentration gradually decreased in tumors, EGF-QDs progressively accumulated in tumors. On delayed imaging at 24 h, tumor fluorescence decreased to near-baseline levels for both QD and EGF-QD. Ex vivo whole-organ fluorescence, tissue homogenate fluorescence, and confocal microscopic analyses confirmed tumor-specific accumulation of EGF-QD at 4 h. Immunofluorescence images showed diffuse colocalization of EGF-QD fluorescence within EGFR-expressing tumor parenchyma compared with patchy perivascular sequestration of QD.
Conclusion: These results represent the first pharmacokinetic characterization of a robust EGFR imaging nanoprobe. The measurable contrast enhancement of tumors 4 h after systemic administration of EGF-QD and its subsequent normalization at 24 h imply that this nanoprobe may permit quantifiable and repetitive imaging of EGFR expression.
Tunable theranostics: innovative strategies in combating oral cancer.
Uthman A, Al-Rawi N, Saeed M, Eid B, Al-Rawi N PeerJ. 2024; 12:e16732.
PMID: 38188167 PMC: 10771769. DOI: 10.7717/peerj.16732.
Nizzero S, Li F, Zhang G, Venuta A, Borsoi C, Mai J Acta Biomater. 2019; 97:501-512.
PMID: 31386927 PMC: 9646250. DOI: 10.1016/j.actbio.2019.08.002.
Kim H, Cho M, Choi H, Lee B, Choi Y Theranostics. 2019; 9(4):1085-1095.
PMID: 30867817 PMC: 6401407. DOI: 10.7150/thno.29719.
Atha D, Nagy A, Steinbruck A, Dennis A, Hollingsworth J, Dua V J Nanobiotechnology. 2017; 15(1):79.
PMID: 29121949 PMC: 5679359. DOI: 10.1186/s12951-017-0312-3.
Subcellular Behaviour Evaluation of Nanopharmaceuticals with Aggregation-Induced Emission Molecules.
Xue X, Xu J, Wang P, Liang X J Mater Chem C Mater. 2016; 4(14):2719-2730.
PMID: 27042309 PMC: 4816494. DOI: 10.1039/C5TC03651H.